WO2007143290A3 - Delayed-release compositions of extended release forms of venlafaxine - Google Patents

Delayed-release compositions of extended release forms of venlafaxine Download PDF

Info

Publication number
WO2007143290A3
WO2007143290A3 PCT/US2007/067397 US2007067397W WO2007143290A3 WO 2007143290 A3 WO2007143290 A3 WO 2007143290A3 US 2007067397 W US2007067397 W US 2007067397W WO 2007143290 A3 WO2007143290 A3 WO 2007143290A3
Authority
WO
WIPO (PCT)
Prior art keywords
release
venlafaxine
delayed
polymers
core formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/067397
Other languages
French (fr)
Other versions
WO2007143290A2 (en
Inventor
Krishna Vishnupad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROSCI Inc
Original Assignee
NEUROSCI Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEUROSCI Inc filed Critical NEUROSCI Inc
Priority to EP07761266A priority Critical patent/EP2023906A2/en
Priority to CA002654361A priority patent/CA2654361A1/en
Publication of WO2007143290A2 publication Critical patent/WO2007143290A2/en
Publication of WO2007143290A3 publication Critical patent/WO2007143290A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present disclosure relates to a delayed controlled release composition of at least one form of venlafaxine. According to the disclosure a delayed controlled release composition of venlafaxine hydrochloride is provided by a blend of polymers in the core formulation. The core formulation having extended release polymers is coated with a non-permeable polymer blend formed of a water in-soluble polymer and an enteric coating polymer, which does not release the active drug in either acid or base for up to about 4 hours. Upon disintegration of the non-permeable coating the active drug is released in a sustained manner due to the polymers within the core formulation. The delayed release prevents the substantial release of venlafaxine into the stomach.
PCT/US2007/067397 2006-06-07 2007-04-25 Delayed-release compositions of extended release forms of venlafaxine Ceased WO2007143290A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07761266A EP2023906A2 (en) 2006-06-07 2007-04-25 Delayed-release compositions of extended release forms of venlafaxine
CA002654361A CA2654361A1 (en) 2006-06-07 2007-04-25 Delayed-release compositions of extended release forms of venlafaxine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81154706P 2006-06-07 2006-06-07
US60/811,547 2006-06-07

Publications (2)

Publication Number Publication Date
WO2007143290A2 WO2007143290A2 (en) 2007-12-13
WO2007143290A3 true WO2007143290A3 (en) 2008-10-16

Family

ID=38802169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/067397 Ceased WO2007143290A2 (en) 2006-06-07 2007-04-25 Delayed-release compositions of extended release forms of venlafaxine

Country Status (3)

Country Link
EP (1) EP2023906A2 (en)
CA (1) CA2654361A1 (en)
WO (1) WO2007143290A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
US8945622B2 (en) 2009-03-09 2015-02-03 Council Of Scientific And Industrial Research Sustained release composition of therapeutic agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703044B1 (en) * 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703044B1 (en) * 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations

Also Published As

Publication number Publication date
WO2007143290A2 (en) 2007-12-13
EP2023906A2 (en) 2009-02-18
CA2654361A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
WO2009113703A3 (en) Orally-disintegrating solid preparation
NZ572760A (en) A delayed release drug formulation comprising a coating comprising a low amylose starch and a Eudragit acrylate polymer
WO2011049309A3 (en) Pharmaceutical composition with both immediate and extended release characteristics
WO2008064163A3 (en) Polymer coated drug-ion exchange resins and methods
WO2008149440A1 (en) Medicinal film preparation with rapidly dissolving property and flexibility
NZ594738A (en) Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
CA2661102C (en) Thiophene derivatives as s1p1/edg1 receptor agonists
WO2010049433A3 (en) Water insoluble polymer: starch-based film coatings for colon targeting
ME02695B (en) Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2008098019A3 (en) Polymer formulations for delivery of bioactive agents
WO2010075072A3 (en) Long circulating nanoparticles for sustained release of therapeutic agents
RU2010116863A (en) BUPROPION HYDROBROMIDE AND ITS THERAPEUTIC APPLICATIONS
WO2010019239A3 (en) Pharmaceutical composition of n- [2,4-bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide and administration thereof
WO2008135090A8 (en) Solid dosage forms comprising an enteric coating with accelerated drug release
WO2008132712A3 (en) Combination pharmaceutical compositions
WO2008157635A3 (en) Synthetic bile acid composition, method, and preparation
WO2011053003A3 (en) Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer
WO2012085043A3 (en) Rapidly disintegrating, solid coated dosage form
WO2009034431A3 (en) Controlled-release dosage forms for varenicline
EP2199341A3 (en) Polylactic acid/polycarbonate resin composition and molded product using the same
WO2008071407A3 (en) Coated pellets
WO2009153461A3 (en) Method for the synthesis of 7, 8-dimethoxy-l, 3-dihydro-2h-3-benzazepin-2-one, and the application thereof to the synthesis of ivabradine and the addition salts thereof with a pharmaceutically acceptable acid
WO2008026048A3 (en) Stable injectable pharmaceutical compositions of docetaxel
WO2010116382A3 (en) Stable pharmaceutical compositions of diclofenac
TW200637537A (en) Pharmaceutical composition containing sibutramine free base and manufacturing method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07761266

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2654361

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007761266

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU